NCT03483116View on ClinicalTrials.gov

A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

711

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Rotavirus Infections
Interventions
BIOLOGICAL

RV3-BB

Oral administration

BIOLOGICAL

Placebo

Oral administration

Trial Locations (1)

Unknown

Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre

Sponsors
All Listed Sponsors
lead

Murdoch Childrens Research Institute

OTHER